Intravitreal anti-VEGF treatments have shown dramatic visual benefits for nAMD patients.7, 8, 9 However, some AMD patients have incomplete responses to anti-VEGF drugs,7, 8, 9 and over the prolonged treatment course, persistent or recurrent disease activity can lead to poor vision outcomes.10, 11, 12 The reason why some nAMD patients are partial responders or nonresponders to anti-VEGF drugs is not clear,7, 8, 9, 10, 11, 12 and some factor(s) other than VEGF could be involved in nAMD progression. Here, VEGFA is linked to age-related macular degeneration.